Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Skovsgaard

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Cancer Chemotherapy and Pharmacology|January 4, 2001
Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III studyD Nielsen, P Dombernowsky, S K Larsen, et al.
Biochemical Pharmacology|June 17, 2000
Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposideD Nielsen, C Maare, J Eriksen, et al.
Biochemical Pharmacology|June 1, 1990
In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analoguesE Friche, P B Jensen, H Roed, et al.
Biochemical Pharmacology|September 15, 1989
Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cellsM Sehested, N Bindslev, E J Demant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancerM Ryberg, D Nielsen, T Skovsgaard, et al.
British Journal of Cancer|July 1, 1990
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cellsM Sehested, T Skovsgaard, P B Jensen, et al.
Cancer Treatment Reports|July 1, 1978
Clinical trial of rubidazone in solid tumors and malignant lymphomasT Skovsgaard, H H Hansen, H T Mouridsen, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1981
Cross resistance and cellular uptake of 4'-O-methyldoxorubicin in experimental tumors with acquired resistance to doxorubicinA Di Marco, T Skovsgaard, A M Casazza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1990
Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III studyD Nielsen, P Dombernowsky, T Skovsgaard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1993
A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPAG Sölétormos, D Nielsen, V Schiøler, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Cancer Chemotherapy and Pharmacology|January 4, 2001
Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III studyD Nielsen, P Dombernowsky, S K Larsen, et al.
Biochemical Pharmacology|June 17, 2000
Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposideD Nielsen, C Maare, J Eriksen, et al.
Biochemical Pharmacology|June 1, 1990
In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analoguesE Friche, P B Jensen, H Roed, et al.
Biochemical Pharmacology|September 15, 1989
Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cellsM Sehested, N Bindslev, E J Demant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancerM Ryberg, D Nielsen, T Skovsgaard, et al.
British Journal of Cancer|July 1, 1990
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cellsM Sehested, T Skovsgaard, P B Jensen, et al.
Cancer Treatment Reports|July 1, 1978
Clinical trial of rubidazone in solid tumors and malignant lymphomasT Skovsgaard, H H Hansen, H T Mouridsen, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1981
Cross resistance and cellular uptake of 4'-O-methyldoxorubicin in experimental tumors with acquired resistance to doxorubicinA Di Marco, T Skovsgaard, A M Casazza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1990
Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III studyD Nielsen, P Dombernowsky, T Skovsgaard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1993
A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPAG Sölétormos, D Nielsen, V Schiøler, et al.
Pageof 8